Strategies adopted by gastric pathogen Helicobacter pylori for a mature biofilm formation: Antimicrobial peptides as a visionary treatment

Gupta, Nidhi; Kumar, Ajay; Verma, Vijay

doi:10.1016/j.micres.2023.127417

Cited by 4 publications

(3 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biofilm acts as a shelter for internal bacteria and evades the host immune system [ 12 , 42 ]. Therefore, if the prepared nanoparticles are able to penetrate the biofilm effectively, their killing efficiency within the biofilm can be greatly improved [ 10 ].…”

Section: Resultsmentioning

confidence: 99%

Copper-Bearing Metal-Organic Framework with Mucus-Penetrating Function for the Multi-Effective Clearance of Mucosal Colonized Helicobacter pylori

Shu,

Zhang,

Zhang

et al. 2024

Research

View full text Add to dashboard Cite

Helicobacter pylori colonizes over 50% of people worldwide. Biofilm formation through penetrating gastric mucus and resistance acquired by H. pylori markedly reduces the efficacy of traditional antibiotics. The present triple therapy and bismuth-based quadruple therapy inevitably causes intestinal flora disturbance and fails to address the excessive H. pylori -triggered inflammatory response. Herein, a mucus-permeable therapeutic platform (Cu-MOF@NF) that consists of copper-bearing metal-organic framework (Cu-MOF) loaded with nitrogen-doped carbon dots and naturally active polysaccharide fucoidan is developed. The experimental results demonstrate that Cu-MOF@NF can penetrate the mucus layer and hinder H. pylori from adhering on gastric epithelial cells of the stomach. Notably, released Cu 2+ can degrade the polysaccharides in the biofilm and interfere with the cyclic growing mode of “bacterioplankton ↔ biofilm”, thereby preventing recurrent and persistent infection. Compared with traditional triple therapy, the Cu-MOF@NF not only possesses impressive antibacterial effect (even include multidrug-resistant strains), but also improves the inflammatory microenvironment without disrupting the balance of intestinal flora, providing a more efficient, safe, and antibiotic-free new approach to eradicating H. pylori .

show abstract

Section: Resultsmentioning

confidence: 99%

Copper-Bearing Metal-Organic Framework with Mucus-Penetrating Function for the Multi-Effective Clearance of Mucosal Colonized Helicobacter pylori

Shu,

Zhang,

Zhang

et al. 2024

Research

View full text Add to dashboard Cite

show abstract

“…The other two review-types focused on biofilm matrix dynamics [157] and the severity of biofilms in disease [158]. One review-type article focused on the stomach pathogen Helicobacter pylori [159], whilst one focused on bacteriocins [160].…”

Section: Review-typementioning

confidence: 99%

A Comprehensive Review of Recent Research into the Effects of Antimicrobial Peptides on Biofilms—January 2020 to September 2023

Fontanot,

Ellinger,

Unger

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Microbial biofilm formation creates a persistent and resistant environment in which microorganisms can survive, contributing to antibiotic resistance and chronic inflammatory diseases. Increasingly, biofilms are caused by multi-drug resistant microorganisms, which, coupled with a diminishing supply of effective antibiotics, is driving the search for new antibiotic therapies. In this respect, antimicrobial peptides (AMPs) are short, hydrophobic, and amphipathic peptides that show activity against multidrug-resistant bacteria and biofilm formation. They also possess broad-spectrum activity and diverse mechanisms of action. In this comprehensive review, 150 publications (from January 2020 to September 2023) were collected and categorized using the search terms ‘polypeptide antibiotic agent’, ‘antimicrobial peptide’, and ‘biofilm’. During this period, a wide range of natural and synthetic AMPs were studied, of which LL-37, polymyxin B, GH12, and Nisin were the most frequently cited. Furthermore, although many microbes were studied, Staphylococcus aureus and Pseudomonas aeruginosa were the most popular. Publications also considered AMP combinations and the potential role of AMP delivery systems in increasing the efficacy of AMPs, including nanoparticle delivery. Relatively few publications focused on AMP resistance. This comprehensive review informs and guides researchers about the latest developments in AMP research, presenting promising evidence of the role of AMPs as effective antimicrobial agents.

show abstract

“…The name "Helicobacter pylori" reflects the characteristics of the bacterium. "Helicobacter" refers to its helical or spiral shape, while "pylori" indicates its association with the pylorus, which is the lower part of the stomach that connects to the small intestine [9]. H. pylori has specialized adhesions (proteins) on its surface that help it adhere to the epithelial cells of the stomach lining, allowing it to establish an infection.…”

Section: Introductionmentioning

confidence: 99%

Review on Helicobacteriosis Associated Diseases

Almashhadany,

Mohammed,

Aljoborey

2023

ijmst

View full text Add to dashboard Cite

Helicobacteriosis is a bacterial infection caused by Helicobacter pylori (H.pylori)(HP). which was discovered in 1982 by Australian scientists Barry Marshall and Robin Warren, who were later awarded the Nobel Prize in 2005.Epidemiological evidence has shown that H.pylori colonizes the upper gastrointestinal tract(GIT), and the infection is one of the most common human bacterial pathogens worldwide, with 4.4 billion infected individuals in 2015, but the prevalence varies according to situation and hygiene principles. Since this first isolation, it has become apparent that this organism may be one of the most common bacterial pathogens of humans, and it is one of the risk factors for adenocarcinoma. Thus, it was categorized as a group 1 carcinogen in 1994 by the World Health Organization (WHO). New infections with H.pylori are thought to occur as a consequence of direct human-to-human transmission, via either an oral-oral or fecal-oral route or both. H.pylori has been detected in stool, saliva, vomitus, and gastric refluxate, the material that has been subject to reflux, principally stomach acid that has leaked up into the esophagus. Clinically, H. pylori infection in humans is related to chronic gastritis, peptic ulceration, duodenal ulcer, and gastric cancer in addition to mucosa-associated lymphoid malignancies.According to the World Health Organization (WHO) estimates available at that time, it was supposed that about 4.4 billion infected individuals in 2015 were infected with H. pylori. These estimations can vary and are subject to change over time as recent investigations and information become obtainable. The prevalence of H. pylori is complex and affected by several factors, comprising age, clinical outcomes, geographical location, and socioeconomic status. A higher incidence was reported in unhygienic and economically poor areas; the rate of H. pylori infection in Africa, South America, and Asia was significantly higher than that in Western Europe, North America, and Australia. However, the disease spectrum of H. pylori infection shows a wide range of clinical aspects, including gastrointestinal diseases and extra gastric manifestations. In this review, we have described the general scope of these diseases.

show abstract

Strategies adopted by gastric pathogen Helicobacter pylori for a mature biofilm formation: Antimicrobial peptides as a visionary treatment

Cited by 4 publications

References 171 publications

Copper-Bearing Metal-Organic Framework with Mucus-Penetrating Function for the Multi-Effective Clearance of Mucosal Colonized Helicobacter pylori

Copper-Bearing Metal-Organic Framework with Mucus-Penetrating Function for the Multi-Effective Clearance of Mucosal Colonized Helicobacter pylori

A Comprehensive Review of Recent Research into the Effects of Antimicrobial Peptides on Biofilms—January 2020 to September 2023

Review on Helicobacteriosis Associated Diseases

Contact Info

Product

Resources

About